Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Microba Life Sciences Limited ( (AU:MAP) ).
Microba Life Sciences Limited reported significant growth in its core testing products, with record sales of MetaXplore and increasing adoption of MetaPanel in both Australia and the UK. The company achieved a 30% increase in FY25 revenue, driven by strategic focus on high-value products and a successful capital raise, positioning it for sustained growth and market expansion.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited is a leader in microbiome diagnostics and therapeutics, focusing on innovative testing solutions such as MetaXplore and MetaPanel. The company operates primarily in Australia and the United Kingdom, targeting gastrointestinal health and pathogen detection through advanced clinical tests.
Average Trading Volume: 293,166
Technical Sentiment Signal: Sell
Current Market Cap: A$54.08M
See more data about MAP stock on TipRanks’ Stock Analysis page.